The control of bone remodeling by neuropeptide Y receptors

[1]  J. Eisman,et al.  Hypothalamic Regulation of Cortical Bone Mass: Opposing Activity of Y2 Receptor and Leptin Pathways , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  S. Brain,et al.  Neuropeptides and their receptors: innovative science providing novel therapeutic targets , 2006, British journal of pharmacology.

[3]  S. Allison,et al.  Hypothalamic Control of Bone Formation: Distinct Actions of Leptin and Y2 Receptor Pathways , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  Masaki Noda,et al.  Leptin regulation of bone resorption by the sympathetic nervous system and CART , 2005, Nature.

[5]  R. Schlienger,et al.  Use of β-Blockers and Risk of Fractures , 2004 .

[6]  P. Vestergaard,et al.  Fracture Risk in Perimenopausal Women Treated with Beta-Blockers , 2004, Calcified Tissue International.

[7]  J. Pasco,et al.  β‐Adrenergic Blockers Reduce the Risk of Fracture Partly by Increasing Bone Mineral Density: Geelong Osteoporosis Study , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  C. Schwarzer,et al.  Synergistic Effects of Y2 and Y4 Receptors on Adiposity and Bone Mass Revealed in Double Knockout Mice , 2003, Molecular and Cellular Biology.

[9]  C. Schwarzer,et al.  Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. , 2002, Diabetes.

[10]  Patricia Ducy,et al.  Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.

[11]  G. Thomas,et al.  Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.

[12]  A. Togari,et al.  Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. , 2001, Biochemical pharmacology.

[13]  P. Widdowson,et al.  Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. , 2000, European journal of pharmacology.

[14]  Arndt F Schilling,et al.  Leptin Inhibits Bone Formation through a Hypothalamic Relay A Central Control of Bone Mass , 2000, Cell.

[15]  M. Schwartz,et al.  Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. , 1999, Diabetes.

[16]  G. Bilbe,et al.  Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. , 1998, Bone.

[17]  T. Nagatsu,et al.  Expression of mRNAs for neuropeptide receptors and β-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells , 1997, Neuroscience Letters.

[18]  T. Hökfelt,et al.  Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. , 1997, Neuroendocrinology.

[19]  R. Palmiter,et al.  Attenuation of the Obesity Syndrome of ob/ob Mice by the Loss of Neuropeptide Y , 1996, Science.

[20]  A. Kreicbergs,et al.  The development of autonomic innervation in bone and joints of the rat. , 1996, Journal of the autonomic nervous system.

[21]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[22]  Takao Shimizu,et al.  Identification of Two Isoforms of Mouse Neuropeptide Y-Y1 Receptor Generated by Alternative Splicing , 1995, The Journal of Biological Chemistry.

[23]  J. Bue-Valleskey,et al.  The role of neuropeptide Y in the antiobesity action of the obese gene product , 1995, Nature.

[24]  E. Theodorsson,et al.  Extraction and quantitation of neuropeptides in bone by radioimmunoassay , 1994, Regulatory Peptides.

[25]  J. L. Morris.  Selective constriction of small cutaneous arteries by NPY matches distribution of NPY in sympathetic axons , 1994, Regulatory Peptides.

[26]  A. Tashjian,et al.  Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. , 1993, Bone and mineral.

[27]  M. Ghatei,et al.  Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse. , 1993, Endocrinology.

[28]  M. Schultzberg,et al.  Neuropeptide Y, Tyrosine Hydroxylase and Vasoactive Intestinal Polypeptide‐Immunoreactive Nerve Fibers in the Vertebral Bodies, Discs, Dura Mater, and Spinal Ligaments of the Rat Lumbar Spine , 1993, Spine.

[29]  M. Schultzberg,et al.  Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR‐106–01, ROS 17/2.8, MC3T3‐E1, and Saos‐2) and primary bone cells , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  R. Turner,et al.  Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats , 1991, Neuroscience.

[31]  T. Hökfelt,et al.  Neuropeptide Y: presence in perivascular noradrenergic neurons and vasoconstrictor effects on skeletal muscle blood vessels in experimental animals and man , 1987, Regulatory Peptides.

[32]  D. Larhammar,et al.  Detection of neuropeptide Y and its mRNA in megakaryocytes: enhanced levels in certain autoimmune mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Cooper,et al.  Osteoporosis: trends in epidemiology, pathogenesis and treatment , 2006 .

[34]  A. Bjurholm.  Neuroendocrine peptides in bone , 2004, International Orthopaedics.

[35]  R. Jilka,et al.  Sex steroids and bone. , 2002, Recent progress in hormone research.

[36]  C. Bünger,et al.  Vasoconstrictive action of neuropeptide Y in bone. The porcine tibia perfused in vivo. , 1994, Acta orthopaedica Scandinavica.